Generic Semaglutide Hits 33% Share, Mounjaro India Sales Decline to ₹1.14 B
Generic semaglutide captured 33% of India’s GLP-1 market in March, up from 25% in February, with monthly prices as low as $14 and volumes more than doubling post-patent expiry. Lilly’s Mounjaro saw share dip to 64% from 71% and Indian sales fell to 1.14 billion rupees from 1.35 billion rupees.
1. India Market Dynamics
Patent expiry on March 20 triggered a surge in generic semaglutide supply, capturing 33% of India’s GLP-1 segment in March versus 25% in February. Local manufacturers priced the drug as low as $14 per month and more than doubled treatment volumes, with Torrent Pharmaceuticals securing an 8% share and Novo Nordisk retaining roughly 70%.
2. Impact on Lilly’s Mounjaro
Lilly’s tirzepatide treatment Mounjaro saw its India market share decline to 64% from 71% in one month, driving sales down to 1.14 billion rupees in March from 1.35 billion rupees in February despite ongoing patent protection. This early revenue dip highlights emerging pricing pressure even before generic tirzepatide launches.
3. Future Patent Expirations and Pricing
Semaglutide protection will expire in additional emerging markets such as Brazil later this year, suggesting similar low-price competition could emerge. Investors will monitor how swiftly global pricing and share dynamics mimic the rapid shifts seen in India and assess potential revenue impacts for all GLP-1 products.